Landscapes / Targets
complement C5
11 drugs act on complement C5, in 36 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs11
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Complement inhibitor |
Approved | 7 Dec 2026soonPhase 3 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 7 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | NMOSD, Neuromyelitis Optica Spectrum Disorders | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 15 Dec 2026soonPhase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 15 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, gMG | ||||
| Open drug page | |||||
Monoclonal antibody |
Roche · Public ROG.SW |
Approved | 18 Apr 2027Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 18 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome | ||||
| Open drug page | |||||
Complement inhibitor |
Approved | 12 May 2027Phase 2/3 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 12 May 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis | ||||
| Open drug page | |||||
Complement inhibitor |
Approved | 25 Jun 2027Phase 4 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 25 Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, gMG and 13 more | ||||
| Open drug page | |||||
Complement inhibitor |
Regeneron · Public REGN |
Approved | 31 Jul 2028Phase 3 trial completes | ||
| How it works | Blocks part of the complement system | ||||
| Next date | 31 Jul 2028 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy (GA) and 3 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved in the EU | Jul 2028Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Jul 2028 · Phase 2 trial completes | ||||
| Also tested for | Acute Respiratory Distress Syndrome (ARDS), ARDS and 2 more | ||||
| Open drug page | |||||
Small interfering RNA |
Regeneron · Public REGN |
Phase 3 | 31 Jul 2028Phase 3 trial completes | ||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | 31 Jul 2028 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis and 2 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Dec 2027Phase 2 trial completes | |||
| Next date | 30 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | PNH - Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria and 2 more | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2028Phase 2 trial completes | |||
| Next date | Dec 2028 · Phase 2 trial completes | ||||
| Also tested for | Glomerulonephritis | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Sep 2027Phase 1 trial completes | |||
| Next date | 30 Sep 2027 · Phase 1 trial completes | ||||
| Also tested for | PNH - Paroxysmal Nocturnal Hemoglobinuria, Antiphospholipid Syndrome (APS) and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 11 of 11 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026